Completed PHASE3 INTERVENTIONAL NCT00002393

A Study of Indinavir Taken With or Without DMP 266

A Phase III, Double-Blind, Placebo-Controlled, Multicenter Study to Determine the Effectiveness and Tolerability of the Combination of DMP 266 and Indinavir Versus Indinavir in HIV-Infected Patients Receiving Nucleoside Analogue (NRTI) Therapy

Sponsor: Dupont Merck

Conditions HIV Infections

Interventions Efavirenz Indinavir sulfate

Updated 5 times since 2017 Last updated: Jun 23, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00002393, this PHASE3 trial focuses on HIV Infections and remains completed. Sponsored by Dupont Merck, it has been updated 5 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dupont Merck

Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Augusta, United States , Calgary, Canada , Chicago, United States , Hampton, United States , Lexington, United States , Nashville, United States , New Orleans, United States , New York, United States , Ottawa, Canada , Rochester, United States and 2 more locations